Data completeness
0/8 — Limited
Drug data last refreshed 3h ago · AI intelligence enriched 6d ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
PARASAL SODIUM (aminosalicylate sodium) is an oral tablet NDA product in pre-launch development by Century Therapeutics. The mechanism of action and therapeutic indications have not been disclosed in available data.
Pre-Launch
Pre-launch stage indicates small, focused teams building infrastructure for eventual market entry; significant growth potential post-approval.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
PARASAL SODIUM is in pre-launch phase with only 3 linked job openings concentrated in Manufacturing and R&D—typical for products preparing for regulatory submission and scale-up. Career growth depends on regulatory approval success and commercial launch execution.
Sr. ManagerEngineering Associate/Associate Engineer
Worked on PARASAL SODIUM at Century Therapeutics? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.